BMEA
Biomea Fusion·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BMEA
Biomea Fusion, Inc.
A clinical-stage biopharmaceutical company that develops novel covalent small molecules for cancers and metabolic diseases
Biological Technology
08/09/2017
04/16/2021
NASDAQ Stock Exchange
106
12-31
Common stock
900 Middlefield Road, 4th Floor, Redwood City, California 94063
--
Biomea Fusion, Inc., was incorporated under the laws of the State of Delaware on August 9, 2017. The Company is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecule drugs for the treatment of patients with metabolic diseases and genetically defined cancers.
Company Financials
EPS
BMEA has released its 2025 Q3 earnings. EPS was reported at -0.27, versus the expected -0.29, beating expectations. The chart below visualizes how BMEA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
